These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2472120)

  • 21. Cut-off levels for maternal plasma alpha-fetoprotein in the diagnosis of neural tube defects: validation of the use of multiples of the normal median.
    Tovey KC; Gerson M
    Br J Obstet Gynaecol; 1979 Jul; 86(7):507-15. PubMed ID: 89862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-trimester screening for neural tube defects using alpha-fetoprotein.
    Bredaki FE; Poon LC; Birdir C; Escalante D; Nicolaides KH
    Fetal Diagn Ther; 2012; 31(2):109-14. PubMed ID: 22377693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of neural tube defects in South Australia, 1966-91: effectiveness and impact of prenatal diagnosis.
    Chan A; Robertson EF; Haan EA; Keane RJ; Ranieri E; Carney A
    BMJ; 1993 Sep; 307(6906):703-6. PubMed ID: 8401091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated maternal serum alpha-fetoprotein with normal ultrasound: is amniocentesis always appropriate? A review of 26,069 screened patients.
    Richards DS; Seeds JW; Katz VL; Lingley LH; Albright SG; Cefalo RC
    Obstet Gynecol; 1988 Feb; 71(2):203-7. PubMed ID: 2447540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amniotic fluid acetylcholinesterase measurement in the prenatal diagnosis of open neural tube defects. Second report of the Collaborative Acetylcholinesterase Study.
    Wald N; Cuckle H; Nanchahal K
    Prenat Diagn; 1989 Dec; 9(12):813-29. PubMed ID: 2483269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sonography, a complementary examination to alpha-fetoprotein testing for fetal neural tube defects.
    Hashimoto BE; Mahony BS; Filly RA; Golbus MS; Anderson RL; Callen PW
    J Ultrasound Med; 1985 Jun; 4(6):307-10. PubMed ID: 2409295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maternal serum alpha-fetoprotein screening in a provincial Health District.
    Woolfson J; Holt EM; Whyman AE; Mabbs DV
    Br J Obstet Gynaecol; 1979 Feb; 86(2):87-90. PubMed ID: 85461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detecting neural tube defects by amniocentesis between 11 and 15 weeks' gestation.
    Crandall BF; Chua C
    Prenat Diagn; 1995 Apr; 15(4):339-43. PubMed ID: 7542382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antecedent circumstances surrounding neural tube defect births in 1990-1991. The Steering Committee of the National Confidential Enquiry into Counselling for Genetic Disorders.
    Williamson P; Alberman E; Rodeck C; Fiddler M; Church S; Harris R
    Br J Obstet Gynaecol; 1997 Jan; 104(1):51-6. PubMed ID: 8988697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maternal serum alpha-fetoprotein and previous neural tube defects.
    Wald N; Barker S; Peto R; Brock DJ; Bonnar J
    Br J Obstet Gynaecol; 1976 Mar; 83(3):213-6. PubMed ID: 56196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prenatal detection of open neural tube defects in a mass screening program by determination of alpha-fetoprotein concentration in maternal serum].
    Zwahr C; Körner H; Tinschert S; Horn A; Schulze M; Voigt M
    Zentralbl Gynakol; 1988; 110(3):158-67. PubMed ID: 2452529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neural tube defects: epidemiology, detection, and prevention.
    Cohen FL
    J Obstet Gynecol Neonatal Nurs; 1987; 16(2):105-15. PubMed ID: 2437270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy of a serum screening service for neural-tube defects: the South Wales experience.
    Roberts CJ; Hibbard BM; Elder GH; Evans KT; Laurence KM; Roberts A; Woodhead JS; Robertson IB; Hoole M
    Lancet; 1983 Jun; 1(8337):1315-8. PubMed ID: 6190057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The improvement of the antenatal detection of fetal neural tube defects using discriminant analysis.
    Pettit BR; King GS
    Clin Biochem; 1984 Feb; 17(1):46-51. PubMed ID: 6200255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results and benefits of a maternal serum alpha-fetoprotein screening program.
    Milunsky A; Alpert E
    JAMA; 1984 Sep; 252(11):1438-42. PubMed ID: 6206249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amniotic fluid alpha-fetoprotein as a marker in prenatal diagnosis of neural tube defects.
    Weiss RR; Macri JN; Elligers K; Princler GL; McIntire R; Waldman TA
    Obstet Gynecol; 1976 Feb; 47(2):148-51. PubMed ID: 55990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for fetal malformations using ultrasound and measurements of alpha-fetoprotein in maternal serum.
    Persson PH; Kullander S; Gennser G; Grennert L; Laurell CB
    Br Med J (Clin Res Ed); 1983 Mar; 286(6367):747-9. PubMed ID: 6186332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Contribution of amniocentesis to prenatal screening of neural tube closing defects: evaluation of 10 years of a center's experience].
    Guibaud S; Capella-Bonnet M; Simplot A
    J Genet Hum; 1985 Sep; 33(3-4):339-45. PubMed ID: 2414399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neural tube defects in Havana City--incidence and prenatal diagnosis.
    Rodriguez PL; Heredero B; Lopez J; Fernandez Yero JL; Oliva RJ
    Zentralbl Gynakol; 1982; 104(20):1325-7. PubMed ID: 6186106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antenatal screening in Oxford for fetal neural tube defects.
    Wald NJ; Cuckle HS; Boreham J; Brett R; Stirrat GM; Bennett MJ; Turnbull AC; Solymar M; Jones N; Bobrow M; Evans CJ
    Br J Obstet Gynaecol; 1979 Feb; 86(2):91-100. PubMed ID: 85462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.